Symbicort SMART Satisfaction From Patient Perspective 2009

This study has been completed.

First Received on July 24, 2009. Last Updated on March 17, 2010 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00946452

Purpose

To characterize the level of asthma control and patient satisfaction amongst diagnosed asthma sufferers who are currently receiving Symbicort Maintenance and Reliever Therapy (SMART) in Malaysia.

Condition
Asthma

Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Prospective
Official Title:	Symbicort SMART Satisfaction From Patient Perspective 2009

Resource links provided by NLM:

MedlinePlus related topics: Asthma

Drug Information available for: Symbicort

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Score level of Satisfaction in Asthma Treatment Questionnaire (SATQ) [ Time Frame: After 3 months on SMART - once ] [ Designated as safety issue: No ]
Score level of Asthma Control Test (ACT) [ Time Frame: After 3 months on SMART - once ] [ Designated as safety issue: No ]

Enrollment:	205
Study Start Date:	August 2009
Study Completion Date:	January 2010
Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years to 59 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Primary care clinic

Criteria

Inclusion Criteria:

Have been prescribed Symbicort SMART (1 or 2 inhalation twice daily) by their Dr's for the past 3 months
Informed consent

Exclusion Criteria:

Symbicort SMART treatment < 3 months
Patients requiring short courses of oral steroids more than twice in a month

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00946452

Locations

Malaysia
Research Site
Petaling Jaya, Selangor, Malaysia

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:

Liam Chong Kin, Professor

UMMC

More Information

No publications provided

Responsible Party:	MC MD, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00946452 History of Changes
Other Study ID Numbers:	NIS-RMY-SYM-2009/1
Study First Received:	July 24, 2009
Last Updated:	March 17, 2010
Health Authority:	Malaysia: Ministry of Health

Keywords provided by AstraZeneca:

Control
Satisfaction

Additional relevant MeSH terms:

Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate

Hypersensitivity
Immune System Diseases
Symbicort
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 09, 2012